Hospital Outcomes
Use of Voraxaze Leads to Reduced Length of Stay and Reduced Mortality Rates
In a retrospective study of Medicare patients with cancer, patients treated with Voraxaze® (glucarpidase) had all of the following benefits compared with nonglucarpidase patients treated with dialysis (dialysis+) and nonglucarpidase patients with or without dialysis treatment (dialysis+/-), respectively ,*:
- Shorter mean hospital length of stay (14.7 days vs 40.2 days and 21.9 days)
- Shorter mean intensive care unit (ICU) length of stay (4.0 days vs 18.2 days in the dialysis+ group)
- Lower inpatient mortality rates (3.3% vs 50.6% and 20.8%)
- Lower 90-day mortality rates (16.7% vs 58.6% and 37.6%)
*Utilizing Medicare inpatient claims data between 2010 and 2017, investigators compared outcomes and healthcare resource utilization between patients treated with Voraxaze (n=30) and patients not treated with Voraxaze (n=701), all of whom had experienced acute kidney injury secondary to inpatient chemotherapy.1
Mean length of stay (LOS) among patients treated with Voraxaze and the non-Voraxaze groups
Source: ClinicoEconomics and Outcomes Research 2019:11 129-144. Adapted and used with permission from Dove Medical Press Ltd.
Rates of mortality among patients treated with Voraxaze and the non-Voraxaze groups
Source: ClinicoEconomics and Outcomes Research 2019:11 129-144. Adapted and used with permission from Dove Medical Press Ltd.
Early vs Late Treatment With Voraxaze
Length of stay in hospital was 54% shorter and ICU stay was 91% shorter with earlier administration of Voraxaze.
|
Early cohort |
Late cohort |
|
|---|---|---|
|
Overall length of stay |
10.0 days |
21.7 days (P=0.002) |
|
Length of hospital stay after Voraxaze |
8.5 days |
14.6 days (P=0.057) |
|
Length of ICU stay |
0.8 days |
8.9 days (P=0.020) |
